Positive end expiratory pressure in acute hypoxemic respiratory failure due to community acquired pneumonia: do we need a personalized approach?

Valentina Paolini, Paola Faverio, Stefano Aliberti, Grazia Messinesi, Giuseppe Foti, Oriol Sibila, Anna Monzani, Federica De Giacomi, Anna Stainer, Alberto Pesci, Valentina Paolini, Paola Faverio, Stefano Aliberti, Grazia Messinesi, Giuseppe Foti, Oriol Sibila, Anna Monzani, Federica De Giacomi, Anna Stainer, Alberto Pesci

Abstract

Background: Acute respiratory failure (ARF) is a life-threatening complication in patients with community acquired pneumonia (CAP). The use of non-invasive ventilation is controversial. With this prospective, observational study we aimed to describe a protocol to assess whether a patient with moderate-to-severe hypoxemic ARF secondary to CAP benefits, in clinical and laboratoristic terms, from the application of a positive end expiratory pressure (PEEP) + oxygen vs oxygen alone.

Methods: Patients who benefit from PEEP application (PEEP-responders) were defined as those with partial pressure of arterial oxygen to the fraction of inspired oxygen (PaO2/FiO2) increase >20% and/or reduction of respiratory distress during PEEP + oxygen therapy compared to oxygen therapy alone. Clinical characteristics and outcomes were compared between PEEP-responders and PEEP-non responders.

Results: Out of 41 patients, 27 (66%) benefit from PEEP application (PEEP-responders), the best response was obtained with a PEEP of 10 cmH2O in 13 patients, 7.5 cmH2O in eight and 5 cmH2O in six. PEEP-responders were less likely to present comorbidities compared to PEEP-non responders. No differences between groups were found in regards to endotracheal intubation criteria fullfillment, intensive care unit admission and in-hospital mortality, while PEEP-responders had a shorter length of hospital stay.

Discussion: The application of a protocol to evaluate PEEP responsiveness might be useful in patients with moderate-to-severe hypoxemic ARF due to CAP in order to personalize and maximize the effectiveness of therapy, and prevent the inappropriate PEEP use. PEEP responsiveness does not seem to be associated with better outcomes, with the exception of a shorter length of hospital stay.

Keywords: Continuous positive airway pressure; Non-invasive ventilation; Pneumonia; Positive end-expiratory pressure; Respiratory failure.

Conflict of interest statement

The authors declare there are no competing interests.

Figures

Figure 1. Description of the CPAP-trial used…
Figure 1. Description of the CPAP-trial used to differentiate PEEP responder patients from PEEP-non responder.
PEEP, Positive End-Expiratory Pressure; CPAP, continuous positive airway pressure; FiO2, fraction of inspired oxygen; RR, respiratory rate.
Figure 2. Definitions of PEEP-responder, FiO2 responder,…
Figure 2. Definitions of PEEP-responder, FiO2 responder, PEEP-non and FiO2-non responder.
PEEP, Positive End-Expiratory Pressure; FiO2, fraction of inspired oxygen; RR, respiratory rate; CPAP, continuous positive airway pressure. Significant changes in clinical or arterial blood gas parameters are intended as an improvement or worsening of 20% compared to baseline.

References

    1. Brambilla AM, Aliberti S, Prina E, Nicoli F, Del Forno M, Nava S, Ferrari G, Corradi F, Pelosi P, Bignamini A, Tarsia P, Cosentini R. Helmet CPAP vs. oxygen therapy in severe hypoxemic respiratory failure due to pneumonia. Intensive Care Medicine. 2014;40:942–949. doi: 10.1007/s00134-014-3325-5.
    1. Corrales-Medina VF, Musher DM, Wells GA, Chirinos JA, Chen L, Fine MJ. Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation. 2012;125:773–781. doi: 10.1161/CIRCULATIONAHA.111.040766.
    1. Cosentini R, Brambilla AM, Aliberti S, Bignamini A, Nava S, Maffei A, Martinotti R, Tarsia P, Monzani V, Pelosi P. Helmet continuous positive airway pressure vs oxygen therapy to improve oxygenation in community-acquired pneumonia: a randomized, controlled trial. Chest. 2010;138:114–120. doi: 10.1378/chest.09-2290.
    1. Ferrer M, Cosentini R, Nava S. The use of non-invasive ventilation during acute respiratory failure due to pneumonia. European Journal of Internal Medicine. 2012;23:420–428. doi: 10.1016/j.ejim.2012.02.011.
    1. Ferrer M, Torres A. Noninvasive ventilation for acute respiratory failure. Current Opinion in Critical Care. 2015;21:1–6. doi: 10.1097/MCC.0000000000000173.
    1. Luo Y, Luo Y, Li Y, Zhou L, Zhu Z, Chen Y, Huang Y, Chen X. Helmet CPAP versus oxygen therapy in hypoxemic acute respiratory failure: a meta-analysis of randomized controlled trials. Yonsei Medical Journal. 2016;57:936–941. doi: 10.3349/ymj.2016.57.4.936.
    1. Nicolini A, Cilloniz C, Piroddi IG, Faverio P. Noninvasive ventilation for acute respiratory failure due to community-acquired pneumonia: a concise review and update. Community Acquired Infection. 2015;2(2):46–50. doi: 10.4103/2225-6482.159224.
    1. Patel BK, Wolfe KS, Pohlman AS, Hall JB, Kress JP. Effect of noninvasive ventilation delivered by helmet vs face mask on the rate of endotracheal intubation in patients with acute respiratory distress syndrome: a randomized clinical trial. Journal of the American Medical Association. 2016;315:2435–2441. doi: 10.1001/jama.2016.6338.
    1. Williams JW, Cox CE, Hargett CW, Gilstrap DL, Castillo CE, Govert JA, Lugogo NL, Coeytaux RR, McCrory DC, Hasselblad V, McBroom AJ, Posey R, Gray R, Sanders GD. Noninvasive positive-pressure ventilation (NPPV) for acute respiratory failure. Agency for Healthcare Research and Quality (US); Rockville: 2012.
    1. Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, Ortqvist A, Schaberg T, Torres A, Van der Heijden G, Read R, Verheij TJM, Joint Taskforce of the European Respiratory Society and European Society for Clinical Microbiology and Infectious Diseases Guidelines for the management of adult lower respiratory tract infections—full version. Clinical Microbiology and Infection. 2011;17(Suppl 6):E1–E59. doi: 10.1111/j.1469-0691.2011.03672.x.

Source: PubMed

3
Sottoscrivi